Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$440M |
| 2 |
IQVIA
IQV
|
+$269M |
| 3 |
AGN
Allergan plc
AGN
|
+$247M |
| 4 |
General Dynamics
GD
|
+$183M |
| 5 |
Fidelity National Information Services
FIS
|
+$158M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$793M |
| 2 |
MDCO
Medicines Co
MDCO
|
+$282M |
| 3 |
ZAYO
Zayo Group Holdings, Inc.
ZAYO
|
+$236M |
| 4 |
S&P Global
SPGI
|
+$175M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.14% |
| 2 | Communication Services | 12.39% |
| 3 | Technology | 10.92% |
| 4 | Industrials | 5.44% |
| 5 | Financials | 3.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $1.65B | 14.14% |
9,300,000
+1,310,000
| +16% | +$247M |
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| $722M | 6.19% |
2,616,500
-1,768,500
| -40% | -$539M |
|
|
3
Fidelity National Information Services
FIS
$21.3B
| $562M | 4.83% |
4,621,208
+1,135,451
| +33% | +$158M |
|
|
4
Centene
CNC
$32.1B
| $431M | 3.7% |
+7,250,000
| New | +$440M |
|
|
5
IQVIA
IQV
$42.8B
| $403M | 3.46% |
3,739,696
+1,885,009
| +102% | +$269M |
|
6
Thermo Fisher Scientific
TMO
$233B
| $353M | 3.03% |
1,243,215
+390,055
| +46% | +$123M |
|
7
Alphabet (Google) Class C
GOOG
$4.18T
| $343M | 2.95% |
5,903,460
+405,400
| +7% | +$27.5M |
|
8
Charter Communications
CHTR
$17.9B
| $316M | 2.71% |
723,328
+40,235
| +6% | +$19.7M |
|
|
PPLI
9
People Inc
PPLI
$2.86B
| $307M | 2.64% |
9,596,124
-1,966,786
| -17% | -$77.9M |
|
10
AbbVie
ABBV
$468B
| $305M | 2.62% |
4,000,000
+1,500,000
| +60% | +$128M |
|
11
Wabtec
WAB
$50.3B
| $304M | 2.61% |
6,322,354
+1,253,167
| +25% | +$86M |
|
|
INFO
12
DELISTED
IHS Markit Ltd. Common Shares
INFO
| $296M | 2.54% |
4,925,538
+2,181,988
| +80% | +$157M |
|
13
Microsoft
MSFT
$3.59T
| $288M | 2.47% |
1,823,720
-362,070
| -17% | -$59.5M |
|
14
Visa
V
$693B
| $284M | 2.44% |
1,763,268
+240,808
| +16% | +$45.4M |
|
15
Elevance Health
ELV
$86.9B
| $284M | 2.44% |
1,250,000
| – | – |
|
|
16
General Dynamics
GD
$104B
| $276M | 2.37% |
2,083,681
+1,102,316
| +112% | +$183M |
|
17
Sherwin-Williams
SHW
$84.1B
| $234M | 2.01% |
1,527,390
+424,065
| +38% | +$76.5M |
|
18
Salesforce
CRM
$171B
| $232M | 2% |
1,614,488
-110,392
| -6% | -$18.9M |
|
19
Cigna
CI
$73.3B
| $221M | 1.9% |
1,250,000
-250,000
| -17% | -$48.5M |
|
20
Alibaba
BABA
$286B
| $218M | 1.88% |
1,123,500
-9,000
| -0.8% | -$1.88M |
|
|
XLRN
21
DELISTED
Acceleron Pharma
XLRN
| $195M | 1.68% |
2,175,000
+175,000
| +9% | +$13.6M |
|
22
Meta Platforms (Facebook)
META
$1.4T
| $181M | 1.56% |
1,087,524
+57,211
| +6% | +$11.2M |
|
23
Equinix
EQIX
$105B
| $176M | 1.51% |
281,933
-134,390
| -32% | -$80.4M |
|
24
Exelixis
EXEL
$13.4B
| $172M | 1.48% |
10,000,000
+2,500,000
| +33% | +$45.7M |
|
25
Iovance Biotherapeutics
IOVA
$3.76B
| $172M | 1.48% |
5,750,000
-500,000
| -8% | -$13.3M |
|
Similar funds
Thomas Steyer's Q1 2020 Portfolio in Review
As of Q1 2020, Thomas Steyer held 136 positions worth $11.7B, down 21% from $14.8B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Thomas Steyer withdrew a net $1.15B in Q1 2020, closing 34 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $793M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Thomas Steyer opened a new position in Centene worth $431M.
- Thomas Steyer's largest Q1 2020 buy was Centene: 7,250,000 shares worth $431M.
- Thomas Steyer added most to IQVIA in Q1 2020, an estimated $269M increase.
- Thomas Steyer's biggest Q1 2020 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $104M.
- Thomas Steyer fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $793M.
- Thomas Steyer's ten largest holdings make up 46% of its $11.7B portfolio in Q1 2020.
- Thomas Steyer opened 17 new positions and closed 34 in Q1 2020.
- Thomas Steyer's portfolio value fell 21% quarter-over-quarter to $11.7B.
Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.